Paxman awarded for its US success
UK scalp cooling company, Paxman, has been awarded the British American Business TransAtlantic Growth (TAG) Award Small Gold Export Award for its US success.
The company has signed delivery agreements in the USA for 250 of its scalp cooling system at 121 clinics.
Paxman’s scalp cooling system reduces the temperature of the scalp by a few degrees immediately before, during and after the administration of chemotherapy.
It’s believed that the damage that chemotherapy causes to the hair follicle can be alleviated by using a cold cap.
Hair loss is one of the most feared and common side effects of chemotherapy treatment and people may refuse chemotherapy treatment because they do not want to lose their hair.
In the UK, Paxman works directly with the NHS and private healthcare providers, including those who offer patients the opportunity to receive their chemotherapy treatment at home.
In the US, Paxman offers a pay-per-treatment and personal cap to give patients an affordable scalp cooling option. The company has set up a HQ in Houston, involving a call centre, pharmacy and logistics, technical service and is employing US training specialists who support providers and patients through the scalp cooling process.
Paxman is placing its scalp cooling systems on a low-cost lease with healthcare providers but will directly bill the patient through the Paxman Hub for their scalp cooling cap and pay-per-use tokens.
CEO Richard Paxman, said: “It is a privilege to be presented with this prestigious award. The US market is the largest in the world, so we are incredibly proud of the progress we have had in our first year since receiving FDA clearance. Our success in the US market, which is key to our global expansion, is also testimony to the growing understanding of the importance of scalp cooling as a way of improving quality of life and giving patients increased control during chemotherapy treatment. I would also like to thank all the team in the US and UK, my family and partner for all their support enabling us to achieve this success.”
The Paxman Scalp Cooling System has received market clearance for use during chemotherapy treatment for breast cancer. The company has filed an application for its system to be used during treatments of patients with solid tumours.